Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutSpecial ReportViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Roy A. Quinlan, PhD

Advertisement

Quinlan is professor emeritus at University of Durham, United Kingdom.
E: [email protected]

Articles by Roy A. Quinlan, PhD

Focus on molecular mechanisms underlying cataract development

ByVanita Berry, PhD,Roy A. Quinlan, PhD,Michel Michaelides, MD, FRCOphth
April 14th 2021

Several hundred genes are associated with congenital forms.

Advertisement

Latest Updated Articles

  • Focus on molecular mechanisms underlying cataract development
    Focus on molecular mechanisms underlying cataract development

    Published: April 14th 2021 | Updated:



Advertisement
Advertisement

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

1

AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives

2

AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081

3

Ocular Therapeutix randomizes first patient in HELIOS-3

4

AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care

5

Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO

  • About
  • Advertise
  • Privacy
  • Editorial Info
  • Editorial Board
  • Terms and Conditions
  • Contact Us
  • Do Not Sell My Personal Information
  • Job Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
EyeCare Network
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us